Xilio Therapeutics (XLO) EBT Growth (3y) (2023 - 2026)
Xilio Therapeutics (XLO) EBT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 9.34% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.39 Bn | 467.60 Bn | 1.35 Bn | 40.43% |
| 5 | Vertex Pharmaceuticals | 122.08 Bn | 114.83 Bn | 2.59 Bn | 12.01% |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -1.05% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | 86.16% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 48.67% |
| 10 | Xilio Therapeutics | 147.13 Mn | -3.17 Mn | - | 15.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.87% |
| Dec 31, 2025 | 21.39% |
| Sep 30, 2025 | 53.93% |
| Jun 30, 2025 | 16.59% |
| Mar 31, 2025 | 13.41% |
| Dec 31, 2024 | 10.88% |
| Sep 30, 2024 | 22.36% |
| Jun 30, 2024 | 13.65% |
| Mar 31, 2024 | -2.11% |
| Dec 31, 2023 | 3.74% |
| Sep 30, 2023 | -5.51% |